RxDoctor Payments Data

Natrajan Subramanian, MD

Clinical Cardiac Electrophysiology · Gainesville, FLNPI 1346446804

Payments from drug & device makers

$15,757in general payments, 2019–2025

Across 157 payments — averaging $100.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$13K
  • Biosense Webster, Inc.$1K
  • E.r. Squibb & Sons, L.L.C.$245
  • Pfizer$240
  • Amgen$192
  • Medtronic$155
  • plus $1K from 21 others

What the payments were for

  • Speaking & faculty fees$12,48579%
  • Food & beverage$3,27221%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,757 in reported general payments places this provider in the 25th percentile of 249 clinical cardiac electrophysiology providers in Florida.

See all clinical cardiac electrophysiology providers in Florida

Medicare billing

Part B allowed, 2024
$1,043,238
Medicare patients
1,420
Services billed
6,795

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban663$633,781
EntrestoSacubitril/Valsartan193$240,989
XareltoRivaroxaban146$161,475
JardianceEmpagliflozin78$75,934
FarxigaDapagliflozin Propanediol42$51,735
MultaqDronedarone Hcl55$50,601
Dofetilide115$26,586
Repatha SureclickEvolocumab25$23,019
Dabigatran EtexilateDabigatran Etexilate Mesylate48$10,692
Flecainide Acetate345$10,496
Praluent PenAlirocumab15$7,157
Metoprolol Succinate347$4,790
Diltiazem 24hr Er (Cd)Diltiazem Hcl120$4,034
Amiodarone Hcl127$3,334
SotalolSotalol Hcl163$3,210

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$240$633,781663 claims
NovartisEntresto$108$240,989193 claims
Johnson & JohnsonXarelto$80$161,475146 claims
Boehringer IngelheimJardiance$99$75,93478 claims
AstraZenecaFarxiga$68$51,73542 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 249 clinical cardiac electrophysiology providers in Florida.

Other clinical cardiac electrophysiology in Gainesville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →